Intimation of Analyst/Investor Meet

Beta Drugs Limited

Scrip Code(s): Not Provided in Transcript

  • Event Type: Q2 and H1 FY27 Earnings Conference Call hosted by PhillipCapital PCG.
  • Date and Time: October 22, 2026 (time not specified in transcript).
  • Purpose: Discussion of quarterly results and strategic business updates.
  • Management Participants: Mr. Rahul Batra (Chairman and Managing Director), Mr. Nipun Arora (CFO), Mr. Ashutosh Shukla (Director of Sales and Marketing), Ms. Rajni Brar (Company Secretary and Compliance Officer), Mr. Natarajan (Head of Strategy).
  • Financial Period Discussed: H1 FY27 (April 2026 - September 2026) and Q2 FY27.
  • Key Financial Highlights:
  • Revenue growth of 29.2% YoY in H1 FY27.
  • EBITDA margin increased from 23.08% to 23.18%.
  • PAT increased by 45% YoY to INR34 crores from INR24 crores.
  • Business Segment Performance:
  • Own-branded business grew 17% YoY in H1 FY27, targeting INR150 crores for FY27.
  • Export sales were INR43 crores in H1 FY27; 76 new dossiers filed including 4 in EU; 872 registrations in pipeline.
  • Nivian Lifesciences (acquisition) delivered 75% growth to INR31 crores in H1 FY27.
  • API business grew 29% YoY.
  • CMO business grew 21% YoY; guided to INR180-190 crores for FY27.
  • Strategic Updates:
  • Evaluating biosimilar market with capital-efficient strategy.
  • Planning oncology manufacturing outside India in focus geographies (LatAm, North Africa, Middle East, APAC).
  • Intermediate plant for API backward integration to be operational by January 2027.
  • Recombinant hormone product (FSH) planned for launch in 2-3 years.
  • Successfully launched 4 new products in FY27; 6 more planned.
  • Regulatory Compliance: Management stated no unpublished price sensitive information (UPSI) was shared during the call. Confirmed zero material impact from NPPA trade margin capping guidelines on business.

Additional Notes Section

  • The call was moderated by Mr. Srisurya K from PhillipCapital PCG Desk.
  • The transcript represents a full recording of the earnings conference call including Q&A session.
  • No financial presentation deck or additional attachments were mentioned in the transcript.
  • The company's IR contact is Valorem Advisors as mentioned during the Q&A.